Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and ComorbiditiesSteven Lim, Sangeetha Jaya Selan, Azraai Bahari Nasruddin et al.|JAMA Internal Medicine|2022Cited by 105
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational StudyJing Lian Suah, Sheamini Sivasampu, Masliyana Husin et al.|International Journal of Infectious Diseases|2022Cited by 79
Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 MonthsEe Vien Low, Kalaiarasu M. Peariasamy, Peter Seah Keng Tok et al.|JAMA Network Open|2022Cited by 24
Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort studyEe Vien Low, Kalaiarasu M. Peariasamy, Mohan Dass Pathmanathan et al.|International Journal of Infectious Diseases|2023Cited by 15
Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence PerspectiveEe Vien Low, Kalaiarasu M. Peariasamy, Hoon Shien Teh et al.|Drugs - Real World Outcomes|2024Cited by 9